Clinical Trials
Study One:
ClinicalTrials.gov – NCT 06318143
MPI:Emmanuel Peprah, PhD
MPI: Obiageli Nnodu, MD
mAnaging siCkle CELl disEase through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE) Study
Sponsor: NIH (National Institute of Health, USA)
Study Type: Pragmatic Implementation Study
Sites: 16 sites across Nigeria
Primary Objective
To evaluate the level of hydroxyurea (HU) adoption among healthcare providers of our task-sharing (SIM) intervention in Nigeria and determine if HU adoption improved patient-level Sickle Cell Disease management and outcomes.
iCTS Role: Trial Monitor
